Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on ®rst-line regimens with stavudine/didanosine and stavudine/lamivudine Recent data have suggested that zidovudine-associated resistance mutations at 215Y and 41L may be observed in zidovudine-naive individuals receiving therapy with stavudine-based regimens [1]. Importantly, these mutations may confer some cross-resistance to other nonthymidine nucleoside analogues such as abacavir [2] and posibly other nucleoside analogues. Data from studies involving zidovudine-based regimens suggest that mutation patterns at viral rebound may differ when lamivudine is the co-therapy compared with when didanosine is the co-therapy [3,4]. The type and frequency of these different nucleoside analogue mutations (NAM) observed when stavudine is combine with didanosine or lamivudine is not established.
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Over 700 Vircogen genotypes (Virco, Belgium) have been performed at the Chelsea and Westminster Hospital over 18 months of availability. We extracted data on reverse transcriptase mutations on patients receiving their ®rst ever regimen containing stavudine plus either didanosine or lamivudine.
Of 47 patients identi®ed, 24 were on didanosine and 23 on lamivudine as co-therapy. The CD4 cell counts, viral load and duration of therapy were similar between the groups (Table 1) . Most patients were receiving a third agent. In the stavudine/lamivudine group, 18 patients were receiving a protease inhibitor (PI) and one a non-nucleoside reverse transcriptase inhibitor (NNRTI). In the stavudine/didanosine group four patients were receiving a PI and 11 an NNRTI. NAM (at codons 41, 67, 70, 210, 215 and 219) were observed in 26 (55%) samples. The mean number of nucleoside type reverse transcriptase mutations (see Table 1 ) was didanosine 1.67 and lamivudine 2.04, with no nucleoside reverse transcriptase inhibitor mutations present in four (17%) didanosine and one (4%) lamivudine recipient. Only nine (19%) patients (six on didanosine, three on lamivudine) had three zidovudine-type mutations or more. The 184V mutation was observed in one (4%) didanosine and 22 (96%) lamivudine recipients (P , 0.001 by chi-squared test) and was the sole mutation in nine (39%) lamivudine patients. The 151M multi-nucleoside resistance mutation was observed in only one individual in the didanosine group. Mutations 65R (two patients), 74V (two) and 75T (one) were only observed with didanosine. Although 41L occurred at a similar frequency (seven didanosine and ®ve lamivudine recipients), 215Y/F was more common with didanosine [11 (46%) versus ®ve (22%) patients], whereas 70R was more common with lamivudine (one didanosine versus six lamivudine). Among the 11 patients who received an NNRTI with stavudine/didanosine, the seven nevirapine recipients all had NNRTI mutations, including four with 181C, two with 103N and one with 190A, implying that despite the absence of zidovudine in a regimen the K103N mutation may be observed.The four efavirenz recipients all had 103N, one sample also having 181C. The one nevirapine plus stavudine/ lamivudine recipient had a 188L mutation only.
In conclusion, NAM were commonly observed in this cohort of zidovudine-naive, stavudine-treated patients who were receiving their ®rst ever antiretroviral regimen. As no pretherapy samples were available, it is possible that some of these mutations may have derived from transmitted zidovudine resistance. However, other groups have also observed the emergence of NAM during stavudine-based therapy [1, 5, 6] , suggesting that these mutations may provide replicative advantage for HIV in the presence of stavudine. As with zidovudine-based therapy, in which the 70R mutation is not commonly observed during combination with didanosine, but is observed during lamivudine cotherapy [3] , the choice of co-nucleoside may in¯uence the mutational pattern observed with stavudine. Patterns observed in this cohort are consistent with zidovudine patterns. Importantly, no nucleoside analogue mutations at rebound are observed in 17% during didanosine co-therapy, whereas 184V is almost invariable when lamivudine is used. Despite a considerable duration of exposure to stavudine (mean 18 months), 45% of patients did not have NAM, suggesting that stavudine, zidovudine and abacavir would remain future treatment options for these individuals. Similarly, only 10 patients (nine with three or more zidovudine mutations plus one with 151M) had mutation patterns consistent with a likely diminished response to abacavir [2] . Polymerase chain reaction for Y chromosome to detect semen in cervicovaginal¯uid: a prerequisite to assess HIV-speci®c vaginal immunity and HIV genital shedding Ensuring that cervicovaginal secretions obtained from sexually active women are free of semen is essential to avoid misinterpretation of the data and accurately assess the immune response in the female genital tract. Similar precautionary measures should be undertaken when analysing genital shedding of HIV in infected women. The presence of semen in cervicovaginal secretions (CVS) may be assessed by the immunochemical detection of semen-derived components by immunocapture assays, including prostatic acid phosphatase, prostaticspeci®c antigen (PSA) [1] and seminal vesicle-speci®c antigen [2] . However, the latter methods may lack speci®city and sensitivity. The present study was carried out to validate a highly sensitive polymerase chain reaction (PCR) for the Y chromosome in the cellular fraction of CVS for detecting contaminating semen in female genital¯uids.
Two hundred and thirteen unselected women attending the National Re Âference Center for Sexually Transmissible Diseases and AIDS in Bangui, Central African Republic participated in the study. We followed the ethical recommendations of the Ministry of Health of the Central African Republic, and verbal informed consent was obtained from all participants. Women entering the study underwent general, genital and pelvic examination, during which CVS were collected as described below. A 7 day follow-up appointment was arranged for all women, and appropriate treatment was provided free of charge for any treatable sexually transmitted infection syndrome or genital pathogen diagnosed. CVS were collected by a standardized nontraumatic 60 s vaginal washing with 3.0 ml of phosphate-buffered saline (PBS), as previously described [3] . The cellular fraction and the cell-free fraction of CVS were separated by centrifugation at 1000 g for 10 min and were kept frozen at À808C until processing.
The detection of PSA and PCR ampli®cation of DNA of the Y chromosome were performed in parallel in all CVS samples collected. The detection and quantitation of PSA were performed in 150 ìl of the acellular fraction of CVS using an immunoenzymatic assay with a threshold of positivity of 0.1 ng/ml (PSA IMX System, Abbott Laboratories, Abbott Park, Chicago, IL, USA). The cutoff for the presence of PSA antigen in cervicovaginal¯uid was 0.4 ng/ml, determined as the mean 2 standard deviations (SD) of the values obtained with this assay in 150 ìl of CVS obtained from 30 healthy childbearing-aged HIV-seronegative Caucasian women claiming to be not sexually active at the time of sampling and recruited as controls. For the PCR of Y chromosome, DNA was extracted from the cellular pellet of CVS using the QIAamp DNA kit, according to the manufacturer's recommendations (Qiagen AG, Basel, Switzerland). One microgram of extracted DNA was processed for Y chromosome DNA ampli®cation, by means of a single PCR using as primer set, SRY3F and SRY3R, speci®c for a 229 bp region in the sex-determining region (SRY), a gene located on the short arm of the Y chromosome, as described [4] . In order to control the quality of extracted DNA and the lack of PCR inhibitors, the ubiquitous â-globin gene was ampli®ed by PCR.
A total of 213 women (mean age 27 years; range 15± 48) were eligible for enrollment. None refused to participate in the study. The median age of ®rst sexual intercourse was 16 years, with a median of two (range 1±8) reported lifetime partners. Forty-four women were found to be seropositive for HIV-1 (20.6%). DNA extracted from the cellular pellet of CVS was tested positive by PCR for the â-globin gene in 204 samples (96%). The nine cervicovaginal samples tested negative for the â-globin gene, suggesting poor conservation or a low amount of DNA in these samples, were excluded from the analysis. When tested for the presence of the PSA antigen, 41 of the 204 â-globinpositive CVS samples (20%) showed an optical density above the cutoff of positivity. The mean concentration of PSA antigen AE SD was 19.9 AE 20.0 ng/ml, with important differences among CVS samples. The concentrations of PSA thus ranged from 0.4 to 2 ng/ml in nine samples; from 2.1 to 10 ng/ml in 11 samples; from 10.1 to 50 ng/ml in 11 samples; and were above 50.1 ng/ml in 10 samples (interquartile range 2.9± 39.9). The cellular fractions of the 204 â-globinpositive CVS were further tested for the SRY gene. Seventy-three (36%) samples gave an amplicon as a unique and clearly distinguishable band of 129 base pairs, and were considered to be positive for the Y chromosome. All PSA-containing CVS (n 41, 20% of CVS) were also positive for SRY DNA. Thirty-two CVS samples (16%) were only positive for the presence of the Y chromosome, with no detectable PSA. The number of semen-containing CVS detected by the Y PCR was signi®cantly higher than the number of semen-containing CVS detected by PSA detection (P , 0.001). The remaining 131 (64%) cervicovaginal samples were both PSA and Y chromosome negative.
In the present study, we demonstrate that the PSA immunocapture assay, one of the most sensitive, speci®c and commonly used immunoenzymatic assays available to detect semen in the CVS collected from women practising unprotected sexual intercourse [5] Jejunal cytokine response in AIDS patients with chronic cryptosporidiosis and during immune reconstitution Chronic cryptosporidiosis in AIDS patients was formerly a debilitating illness that frequently resulted in death [1] . With effective antiretroviral therapy, many patients experience complete a resolution of symptoms and suppression [2] , or elimination of the parasite [3, 4] . Although a previous study demonstrated an increase in CD4 T cell numbers in the colonic mucosa of AIDS patients after short-term combination therapy [5] , little information exists on the effects of antiretroviral combination therapy on local cytokine production by the gastrointestinal tract in AIDS after highly active antiretroviral therapy (HAART). To our knowledge no data exist regarding the local intestinal cytokines associated with the control of opportunistic infection or after immuno-reconstitution in AIDS.
We previously demonstrated that the resolution of Cryptosporidium parvum infection in immunocompetent adults is associated with the production of IL-15. In contrast, infection in sensitized individuals is controlled by the production of ã-IFN [6] . The objective of this study is to describe the local cytokine response in the intestines in AIDS patients with chronic cryptosporidiosis, and to document the changes in cytokine pro®les noted when cryptosporidiosis resolves in response to HAART.
Seven AIDS patients with AIDS, chronic diarrhea, cryptosporidiosis, and C. parvum oocysts in their stool participated in the study. A baseline evaluation included a medical examination, the determination of circulating CD4 T cell numbers and HIV viral load. The baseline mean CD4 T cell count was 25 AE 28 cells (range 5± 75) and the mean viral load was 5.82 (log). All patients were antiretroviral experienced. At baseline, two patients were receiving monotherapy with stavudine (biopsied before the availability of protease inhibitors), two patient were receiving combination regimens but with antiviral failure, and two had been heavily pretreated and were off antiviral therapy at the time of enrolment.
Subjects were asked to provide 24 h stool collections for oocyst quantitation as well as to undergo endoscopy with jejunal biopsy. On the basis of previous antiviral exposure, the antiretroviral regimens were modi®ed. Patients were started on azithromycin 600±1200 mg a day and paromomycin 2 g a day (in two to four doses) [7] . Four to 24 weeks later, patients were reassessed for response. In those who demonstrated clinical improvement, the endoscopy was repeated and stools examined for oocysts. Intestinal biopsy specimens were immediately ®xed in diethyl pyrocarbonate-treated paraformal-dehyde (60 min, room temperature), washed in diethyl pyrocarbonate-treated phosphate-buffered saline, and stored in 70% ethanol until sectioning. Cytokine responses were assessed by in-situ hybridization with [35S]-labelled riboprobes for IFNã, transforming growth factor beta (TGFâ), IL-15, and IL-4 using methods previously described [6, 8] . TGFâ was the only cytokine identi®ed in the baseline biopsies and was found in two out of six patients studied.
Out of the seven patients, three resolved their diarrhea, and one improved but did not resolve the infection after modi®cations in antiviral therapy as outlined in These data suggest that several intestinal cytokines are expressed in response to chronic cryptosporidiosis in patients who are receiving antiviral therapy. TGFâ stimulates B cells to switch to the production of IgA. It also participates in the restoration of damaged epithelium. Its expression in chronic infection is consistent with our previous observation of expression in normal volunteers shedding oocysts, and probably re¯ects a response to counteract ongoing injury. By contrast, mRNA for either IL-15 or IFNã and IL-4 could be identi®ed in biopsies from all three patients who had resolved cryptosporidiosis in response to antiretroviral therapy. In previous studies, we noted IFNã and IL-4 as part of the response of sensitized HIV-negative normal volunteers to C. parvum, whereas the expression of IL-15 was associated with the response in naive volunteers. The numbers of patients and biopsies studied here is insuf®cient to determine the timing. However, the sequential expression in subject 5 suggests that perhaps AIDS patients develop a local naive and then a memory response. For now, we can conclude that in AIDS patients who are undergoing immune reconstitution, intestinal cytokine expression increases the associated with the resolution or improvement of Cryptosporidium infection. The patterns of cytokines expressed are similar to those noted in self-limited infection in normal volunteers. There is thus evidence of local as well as systemic immune reconstitution. Three patients resolved infection and were re-studied at 4±24 weeks after the modi®cation of antiviral therapy. [4] .
The purpose of this community-based study, therefore, was to investigate the long-term safety and ef®cacy of a regimen of nevirapine, stavudine and lamivudine in a real world setting. Twenty-six treatment-naive patients were prospectively enrolled in a study of a highly active antiretroviral therapy regimen of nevirapine, stavudine and lamivudine at a community-based clinic. The median age of the group was 43 years (range 25±66), 25 of the patients were men. The median baseline viral load was 38 138 copies/ml (range 4846±212 852 copies/ml), and the median baseline CD4 cell count was 360 cells/mm 3 (range 98±920 cells/mm 3 ). The mecian length of time to follow-up was 31 months (range 8±40 months). Ninety-two per cent (24/26) had viral loads of less than 50 copies/ml at their last visit, with one patient having a viral load of 657 copies/ml, and one being off medication. This group of patients maintained a viral load of less than 50 copies/ml for a mean of 19 months (range 7±38 months). Thirteen of these patients had been virologically suppressed for over 2 years at latest follow-up. The median CD4 cell count at the last follow-up was 575 cells/mm 3 . The regimen of nevirapine, stavudine and lamivudine, therefore, provided a potent and durable response in this population.
This regimen also proved to be remarkably well tolerated, with reports of two cases of peripheral neuropathy secondary to stavudine, but no nevirapineassociated clinical side-effects. Some slight elevations in transaminase levels were observed after initiating therapy; serum glutamic-oxaloacetic transaminase increased from 26.6 to 28.7 U/l, and serum glutamate-pyruvate transaminase increased from 25.8 to 38.6 U/l. However, transaminase levels did not increase in any individual to greater than two times the upper limit of normal at any point, and were not clinically relevant.
This simple nevirapine-based combination regimen of three tablets twice a day, with no food restrictions, provided durable virological suppression for up to 38 months in a community-based cohort of treatmentnaive patients. Highly active antiretroviral therapy containing nevirapine can, therefore, be effectively used as a long-term protease inhibitor-sparing regimen. No loss of virological control was seen in this cohort, reducing concerns for the emergence of NNRTIassociated resistance over time. This study was not designed to look at lipodystrophy. However, lipid abnormalities and fat redistribution have not been associated with nevirapine; indeed, nevirapine has been associated with improvements in hyperlipidemia and lipodystrophy after a switch from protease inhibitors [5] , adding additional appeal for regimens such as the one described here. The lack of both short-and longterm side-effects with this potent regimen also makes it a very attractive alternative for treatment-naive subjects. The improved quality of life associated with a simple regimen and absence of side-effects is likely to impact positively on drug adherence, and could explain the durability of this nevirapine-based antiretroviral regimen in such a high proportion of patients. 
Indinavir and systemic hypertension
The introduction of antiretroviral therapy that includes a protease inhibitor (PI) has changed dramatically the clinical perspectives for HIV-infected individuals [1] . Because the risk of HIV mortality is reduced, the importance of long-term side-effects associated with the use of PI has become a relevant issue [2, 3] . Indinavir, one of the most widely used PI, has been associated with renal calculi and nephropathy [4, 5] . Blood hypertension, as a consequence of indinavir treatment, has not been reported. The aim of this retrospective study was to evaluate the frequency of this side-effect in a cohort of HIV-infected patients receiving indinavir; individuals treated with other PI were used as a reference group. The study population was based on a cohort of HIV-infected patients receiving longitudinal care through the outpatient unit of the Division of Infectious Diseases of Padua, Italy, between January 1997 and June 2000. Inclusion criteria consisted of a duration of PI treatment of at least 6 months and no previous therapy with PI. Individuals with previous hypertension, and con®rmed non-compliance (self-reported or drug-monitored) were excluded. According to an internal protocol, patients were followed at monthly clinical visits, at which time blood samples were drawn and blood pressure was taken. Biochemical parameters and urine analysis were monitored every 4 weeks, CD4 cell counts and HIV-RNA levels were monitored every 12 weeks. In the subset of patients in which hypertension was recorded, at least three repeated measurements of blood pressure were taken during a one month period. In addition, 24 h urine collection in order to check for creatinine clearance, protein and glucose excretion, the renin±angiotensin system, together with renal ultrasonography and a Doppler¯ow study were performed. Hypertension was de®ned as systolic blood pressure of 140 mmHg or higher, diastolic blood pressure of 90 mmHg or higher, or both [6] .
A total of 198 patients were evaluated. Of these, ®ve patients were excluded for the presence of hypertension at baseline, nine for non-compliance and three for lack of follow-up. A study population including 181 patients was thus observed; during a median follow-up period of 34 months (range 6±56), sixty-seven patients (37%) maintained the initial highly active antiretroviral therapy regimen for a median time of 26 months (7± 45), whereas 114 patients (63%) changed their highly active antiretroviral therapy, with a median number of regimens of two (2±6). Indinavir was used in 104 patients (group 1) and other PI (nel®navir, saquinavir, and ritonavir) were used in 77 patients (group 2), which was considered the control group. The baseline characteristics of the two patient groups were well matched for all the considered parameters (Table 1) . At study entry both the mean systolic pressure and the mean diastolic pressure were similar in the two groups: 125 mmHg (110±130, SD AE 10.7) and 81 mmHg (60±85, SD AE 6.1) in group 1 versus 126 mmHg (105±135, SD AE 12.0) and 82 mmHg (70±85, SD AE 6.6) in group 2 (no signi®cant differences were found using the Mann±Whitney test).
During the study period, 31 patients experienced stage 1 or greater blood hypertension: all patients belonged to group 1. The mean systolic pressure was 136 mmHg (105±180, SD AE 17.8) and the mean diastolic pressure was 91 mmHg (60±120, SD AE 12.3) in group 1 compared, respectively, with 125 mmHg (105±138, SD AE 13.0; P , 0.0001 Mann±Whitney test) and 80 mmHg (70±88, SD AE 7.5; P , 0.0001) in group 2. In the 31 patients with hypertension, the mean systolic pressure was 153 mmHg (120±180, SD AE 15.8) and mean diastolic pressure was 100 mmHg (95±120, SD AE 6.2) compared with baseline values of 120 and 80 mmHg, respectively, (P , 0.0001 Wilcoxon rank signed test) (Fig. 1) . In six patients a stage 3 hypertension was recorded, in ®ve a stage 2, and in 20 patients a stage 1.
The proportion of cases with hypertension was higher in men than in women (M : F: 9 : 1), whereas no signi®cant differences were observed between this subgroup of patients and group 2 in terms of age, CD4 cell count, HIV-RNA levels and type of nucleoside reverse transcriptase inhibitors used in the regimens.
No signi®cant changes in renal function were noted, whereas a positive family history for essential hypertension was reported in 18 out of 31 patients (58%).
Blood hypertension was effectively controlled with antihypertensive drugs in 18 patients, in nine indinavir was withdrawn (hypertension recovered in four, whereas it persisted in ®ve cases), and in four patients speci®c therapy was refused because of mild hypertension.
This retrospective analysis showed that indinavir-containing regimens are signi®cantly associated with blood hypertension. The pathogenesis of this side-effect remains unexplained. Further studies are needed to elucidate both the potential role of the prolonged use of previous antiretroviral therapies and the effects of a re-challenge with indinavir therapy. In addition, epidemiological variables such as obesity, alchohol, Comparisons were made between data on subjects in group 1 and group 2 by unpaired Student's t-test (no signi®cant differences were found). a No differences in blood pressure between the two groups were found (Mann±Whitney test). cigarette smoking, and the use of non-steroidal antiin¯ammatory agents should be investigated.
Furthermore, it is of interest that more than half of our 31 patients had a positive family history of hypertension. We could speculate that indinavir, at least in some cases, may trigger latent hypertension, rather than directly cause this effect. These data are in agreement with the absence of renal abnormalities and the normal renin±angiotensin system found in our patients.
Although the retrospective nature of the study did not allow us to con®rm de®nitively the relationship between indinavir and hypertension, an important point emerges from this analysis: blood pressure needs to be carefully monitored in regimens that include indinavir. This is particularly important in patients with hypertension or a family history of hypertension, in whom indinavir should be considered as a second line PI antiretroviral therapy. 
Osteopenia in HIV-infected patients: is it the disease or is it the treatment?
Bone loss is a normal feature of aging. Accelerated bone demineralization is a multifactorial process; recent reports have suggested that HIV infection, perhaps in association with protease inhibitor (PI) therapy, is an additional risk factor for osteopenia [1, 2] . However, changes in bone mineral metabolism, bone histomorphometry or bone mineral density had been described in HIV-infected patients before the era of highly active antiretroviral therapy (HAART) [3±5].
The aim of this study is to de®ne the role of HIV infection and antiretroviral therapy in the development of bone mineral loss. A cross-sectional study was performed with the following patients enrolled: 80 HIV-infected patients [58 men, 22 women, mean age (SD) 41 years (AE 8)]; 26 did not receive treatment; 37 were on HAART that included a PI; 17 were on HAART without a PI (two nucleoside reverse transcriptase inhibitors plus one non-nucleoside reverse transcriptase inhibitor). One hundred healthy seronegative adults matched by age and sex served as controls.
Patients with known factors of osteopenia were excluded (recent history of extended bed rest, previous diagnosis of metabolic bone disease, renal insuf®ciency, hepatic failure, diabetes mellitus or previous diagnosis of other endocrine disease, moderate or severe nutritional alteration, and severe alcohol consumption).
Hologic QDR-4500 SL dual energy X-ray absorptiometry was used to determine the bone mineral density (BMD) of the lumbar spine (L1±L4) and proximal femur, with T and Z scores (T score represents a SD in BMD within the mean of the population at 30; Z score represents a SD in BMD within the mean of the same age and sex group). Using World Health Organization de®nitions of osteopenia and osteoporosis, we classi®ed the patients into the following categories: normal: T score greater than À1; osteopenic: T score from À1 to À2.5; and osteoporotic: T score less than À2.5.
Non-parametric statistical tests (Kruskal±Wallis) were used to compare Z scores for spinal and hip BMD between groups. Normally distributed variables were compared using an analysis of variance. Chi-square and Fisher's exact test were used for categorical variables. Pearson's correlation coef®cient was used to evaluate weight, body mass index, duration of therapy, CD4 cell count, and viral load in relation to BMD.
The characteristics of the 180 subjects included in the study and its most relevant results are summarized in Table 1 .
No differences were found in HIV-infected patients, irrespective of the treatment or type of treatment; however, the HIV-infected patients have lower BMD compared with healthy adults; the difference in BMD Z score between healthy adults and HIV patients was: in the lumbar spine: À0.43 [P 0.001; 95% con®-dence interval (CI) À0.7 to À0.2]; in the femoral neck: À0.68 (P 0.0001; 95% CI À0.91 to À0.44).
BMD was not correlated with HIV categories, viral load, CD4 cell count, duration of therapy, or the presence of lipodystrophy, and was correlated with weight and body mass index (r 0.3; P 0.02).
In relation to the potential role of individual antiretroviral agents on decreased BMD, we found that patients exposed to indinavir (17 patients, as the only PI used) have lower Z scores in the femoral neck compared with treated patients who have not been exposed to indinavir (À1.4 versus À0.7; P 0.02).
Osteopenia was present in 25% of healthy adults and in 67.5% of HIV-infected patients [P 0.00001; odds ratio (OR) 6.2; 95% CI 3.1±12.6]. Osteoporosis was present in 5% of healthy adults and in 21.2% of HIV-infected patients (P 0.00009; OR 5.1; 95% CI 1.7±18.5). Differences in osteopenia or osteoporosis did not reach statistical signi®cance among the HIV patient groups.
In our study, a decrease in BMD and a higher rate of osteopenia and osteoporosis was found in HIV-infected patients compared with non-HIV patients. No clear association was found in relation to the use of HAART or the type of HAART used.
Studies made before the HAART era and a more recent study obtained similar conclusions [3±6] . The hypothesis that the systemic activation of T cells in vivo leads to an osteoprotegerin ligand-mediated increase in osteoclastogenesis and bone loss [7] may explain the interaction of HIV infection and bone mineralization. The lack of differences in the rate of osteopenia and osteoporosis found in HIV-infected patients irrespective of the treatment received has the limitation of the relatively small population included in the study. The difference observed in patients exposed to indinavir with respect to other patients treated in the femoral neck is a very preliminary observation; however, indinavir is the only PI known to alter the activity of osteoblast alkaline phosphatase in vitro [8] .
The aetiology of bone loss in HIV-infected patients, the role of speci®c class toxicity, the clinical implications and the therapeutic or preventative strategies require further investigation. Cidofovir added to highly active antiretroviral therapy in AIDS-associated progressive multifocal leukoencephalopathy Progressive multifocal leukoencephalopathy (PML) is a demyelinating central nervous system disease occurring in HIV-infected as well as in other immunosuppressed patients. Its incidence has been reduced with the use of highly active antiretroviral therapy (HAART) [1] and some cases of cure after HAART have been described [2] . However, it continues to be a disabling disease with a high mortality rate.
De Luca et al. [3] reported that adding cidofovir to HAART results in a more effective control of JC virus, and an improved neurological outcome and survival in patients with AIDS-associated PML than when using HAART alone. We agree with the authors' conclusion about the importance of the early diagnosis and treatment of PML.
We have used cidofovir as a compassionate treatment for PML in eight patients with HIV infection, in addition to HAART. Written informed consent was obtained from every patient. The mean age was 37.5 years and seven patients were men. The risk factor for HIV infection was intravenous drug use in ®ve, and sexual risk relationships in three. The mean CD4 cell count at diagnosis was 78 3 10 6 /l (range 3± 227 3 10 6 /l) and plasma HIV-RNA levels were 78 943 copies/ml (range 122±522 000 copies/ml). Two patients were receiving HAART before the diagnosis of PML. The diagnosis of PML was based on clinical and radiological ®ndings consistent with PML, the detection of JC virus DNA in the cerebrospinal uid, or brain biopsy. PML was the ®rst AIDS-de®ning illness in four patients. The mean duration of symptoms before diagnosis was 22 days (range 7±75 days), and they consisted of focal cerebellum symptoms (N 6), cranial nerve paralysis (N 5), hemiparesis (N 3), and visual loss (N 3). Magnetic resonance imaging revealed bilateral, non-enhancing, hyperintense lesions on T2-weighed images in all patients, without evidence of mass effect. In half of the patients the lesions were located supra-and infra-tentorially. At PML diagnosis, HAART was continued in two patients and started in the other six. Treatment with cidofovir was initiated simultaneously with the diagnosis of PML in two patients.
In six patients, cidofovir was added to HAART at a median of 42 days after the PML diagnosis (range 21± 60 days) because of clinical deterioration. Cidofovir was administered at 5 mg/kg intravenously at 1 week intervals for the ®rst two administrations, and every 2 weeks therafter, with probenecid and saline infusion. Five patients received two cidofovir cycles, one patient received four cycles and two, seven cycles. The low number of cidofovir cycles received by ®ve of the patients was related to their short survival after beginning cidofovir (median 16 days). At follow-up, all patients except two showed clinical and radiological progression. Six patients (75%) died as a result of PML, at a median of 18 days after starting cidofovir (range 12±132 days). The other two remaining patients are still alive and their neurological symptoms, although present, have improved after a follow-up of 180 and 185 days, respectively.
Cidofovir is active against Papovaviridae in vitro [4] , and recently its ef®cacy has been reported in the treatment of PML [3, 5, 6] . We agree with De Luca et al. [3] that patients with PML do not always bene®t from HAART, and cases have occurred during HAART and despite a good virological response, as happened with two of our patients. Therefore, we think that an adjunctive therapy, such as cidofovir, may be useful for the treatment of PML. However, our ®ndings suggest that cidofovir has a very limited effect in patients with PML and advanced HIV-related immunosuppression who are not showing a response to HAART, because the patients died before a signi®cant number of doses of cidofovir could be administered. Considering that our experience is limited to a small number of patients, we think that cidofovir might be a therapeutic option for PML treatment, but should be prescribed in addition to HAART immediately after diagnosis. A simple and rapid magnetic bead separation technique for the isolation of tetramer-positive virus-speci®c CD8 T cells Recent reports on functional impairments within CD8 T cell subpopulations [1±5] focused attention on quantitative assessments of functional activity. However, the expansion and propagation of antigen-speci®c CD8 T cells often requires extensive tissue culture manipulations and frequent re-stimulations. A method that could selectively identify and expand an antigenspeci®c CD8 population would be of value in these quantitative assessments.
Flow cytometric or human leukocyte antigen (HLA) bead sorting of tetrameric-positive virus-speci®c T cells has proved to be of value [6, 7] ; however, it requires ā ow cytometer, is technically demanding and needs conditions of absolute sterility. We have developed an assay that utilizes anti-phycoerythrin-coated MACS beads (Miltenyi Biotec, Auburn, USA) to select positively phycoerythrin-conjugated tetramer peptide complexes admixed with CD8 T cells to obtain and select enriched speci®c populations for in-vitro culture. This simpli®ed method can lead to the rapid expansion of an antigen-speci®c T cell population.
To compare the isolation of virus-speci®c CD8 T cells by anti-phycoerythrin bead separation and¯ow cytometry, an HLA-A Ã 0201-positive cytomegalovirus (CMV)-seropositive donor with 0.43%, CMV-pp65 (495±503: NLVPMVATV)-speci®c tetramer-positive CD8 T cells was identi®ed (Fig. 1a) . We isolated CMV-pp65 CD8 T cells with anti-phycoerythrin MACS beads by the incubation of 5 3 10 6 peripheral blood mononuclear cells (PBMC) for 20 min at 378C with the HLA-A Ã 0201 CMV-pp65-speci®c tetramer [8] . The PBMC were then incubated with 20 ìl antiphycoerythrin MACS beads (Miltenyi Biotec) at 48C for 20 min to label the CMV-pp65-speci®c CD8 T cells. The labelled PBMC were passed through a prewashed (500 ìl of buffer: PBS pH 7.2, 0.5% bovine serum albumin and 2 mM ethylenediamine tetraacetic acid) separation column (Miltenyi Biotec) on a magnet. The column was eluted three times with 500 ìl of buffer to remove the unbound CMV-pp65 tetramernegative PBMC (negative fraction). The separation column containing the phycoerythrin-speci®c magnetic beads bound to the tetramer-positive T cells was removed from the magnet. The column was washed twice again with 500 ìl of buffer then, ®nally, to ensure all the cells were recovered, a plunger was used to elute the labelled CMV-pp65 tetramer-positive CD8 T cells (positive fraction). Simultaneously, 5 3 10 6 PBMC were counterstained with a combination of phycoerythrin-conjugated CMV-pp65 tetramer and uorescein-isothiocyanate-conjugated CD8 monoclonal antibody for¯ow cytometric isolation, performed using standard methods [9] . The CMV-pp65 tetramerpositive, negative and¯uorescence-activated cell sorted (FACS) fractions were cultured in R15-50 medium [RPMI 1640 media supplemented with 15% heatinactivated fetal calf serum, L-glutamine, hepes, 50 IU/ ml IL-2 and penicillin±streptomycin (Biowhittaker, Maryland, USA)] with the addition of pooled irradiated PBMC feeders (at 1 3 10 6 /ml) and anti-CD3 (12F6, Dr J. Wong, Massachusetts, USA).
After 14 days, the lytic activity of the CMV-pp65-speci®c CD8 T cell cultures was assessed in a standard 51 Cr release assay using CMV-pp65 peptide pulsed HLA-A Ã 0201 B cell lymphoma targets. The CMVpp65-speci®c CD8 T cells were added at two effector : target ratios and incubated at 378C, 5% carbon dioxide for 4 h (Fig. 1c) .
The CMV-pp65-speci®c CD8 T cell population was strongly CMV-pp65 tetramer positive after a 14 day in-vitro expansion period (Fig. 1b) , whereas the`negative' fraction remained CMV-pp65 tetramer negative (Fig. 1b) . From a starting population of 5 3 10 6 PBMC, we initially isolated approximately 21.5 3 10 3 tetramer-positive cells (0.43%). This culture was expanded by stimulation with peptide-pulsed irradiated feeders over 14 days, with the result that 33.8% of the CD3/CD8 population were HLA-A Ã 0201 CMVpp65-speci®c tetramer positive (Fig. 1b) . The 51 Cr release assay determined the speci®city and function of the antigen-speci®c CD8 T cells against CMV pp65-peptide pulsed HLA-A Ã 0201 targets. The percentage of speci®c target cell lysis of target cells was compared for anti-phycoerythrin MACS bead-enriched CMV pp65 antigen-speci®c CD8 T cell population and the corresponding expanded effector population, isolated by single-cell sorting using phycoerythrin-conjugated tetrameric complexes and FACS (Fig. 1c) . The negatively sorted T cell population demonstrated nonsigni®cant lysis (, 15%) compared with the positively sorted HLA-A Ã 0201 CMV-pp65-speci®c CD8 population (. 50%) (Fig. 1c) . These data showed that MACS separation with anti-phycoerythrin micro beads is a viable technique for the separation of short-term cell lines and for the cloning of HLA tetrameric complex-labelled antigen-speci®c T cells.
Here we have demonstrated a simple immunomagnetic separation technique that utilizes technology readily available to most immunology laboratories worldwide. The method is speci®c and represents an inexpensive, reliable alternative to cell sorting by¯ow cytometry for the isolation of phycoerythrin-conjugated tetramerpositive T cells. The impact of experiencing lipodystrophy on the sexual behaviour and well-being among HIV-infected homosexual men Of 117 HIV-infected homosexual recipients of highly active antiretroviral therapy (HAART), 50.4% reported lipodystrophy. Experiencing lipodystrophy had a strong impact on the perceived health and con®dence in relationships of these men. An additional decrease in the enjoyment of sex and sexual activity was noted, although this may also be the result of other aspects of HAART use. The ®ndings underline the importance that HIV-infected individuals, who are considering starting HAART, are informed about the possibility of such effects. Clinicians should be aware of the potential impact of HAART on their patients in case side-effects develop.
The use of HAART has been associated with changing views about high-risk sex [1, 2] . In a previous study among homosexual men, not short-time HAART use (, 1 year) in itself, but the ®rst HAART-induced virological and immunological improvements were likely to be associated with the (temporary) increased practice of risk behaviour [3] . Just as is observed for these speci®c favourable consequences of HAART, experiencing side-effects may also in¯uence sexual behaviour in some way. Increasing attention is paid to lipodystrophy, a syndrome marked by the redistribution of body fat, and mostly attributed to the use of protease inhibitors (PI) [4±7] . Because this syndrome is associated with involuntary changes in body composition, we hypothesized that this may have a substantial in¯u-ence on an individual's well-being and behaviour.
We sent a questionnaire to the HIV-positive homosexual men (n 176) who participated in the Amsterdam Cohort Studies, and were now being seen by practitioners and clinicians in Amsterdam. We asked the 59 men who reported lipodystrophy to compare the period of experiencing this syndrome with the period before. Comparisons were made regarding sexual behaviour and well-being (Table 1) , using a ®ve-point scale (1: much less; 2: less; 3: similar; 4: more; 5: much more). A t-test was used to determine whether the mean scores differed from the neutral score (score 3, indicating no change). The 59 men who experienced lipodystrophy reported a drastic decrease in sexual activity (Table 1) . Importantly, they less enjoyed sex less, felt less physically well and were less con®dent in relationships when experiencing lipodystrophy. In analyses of variance, answers were not in¯uenced by sociodemographic characteristics, time of being HIV positive or time since initiating HAART (all P values . 0.05).
This cross-sectional study was somewhat limited by the way in which variables were measured. Lipodystrophy was self-reported, which may have led to an under-or overestimation of the prevalence of`clinical`lipodystrophy. Although some investigators used objective 'metabolic' criteria to de®ne lipodystrophy, most other studies have also based their ®ndings on subjective judgement of the syndrome [4±7]. Furthermore, in-dividuals were asked to recall events afterwards. Recall bias might be introduced depending on the duration and severity of lipodystrophy, as well as the presence of this syndrome at the time of measurement. To what extent recall bias in¯uenced our results, however, is unknown.
In discussing the speci®c impact of experiencing lipodystrophy, one should also take into account changes that occurred as a result of the use of HAART per se. Therefore, we also asked men to compare the entire period of using HAART with the period before (in which they knew they were HIV positive) (data not shown). Over the entire HAART period, no change was reported in self-perceived health and con®dence in relationships, contrasting with the strong decrease over the period of experiencing lipodystrophy. Therefore, lipodystrophy has probably a substantial and speci®c impact on a person's well-being, which can not be attributed to the use of HAART in general. Men who ever experienced lipodystrophy reported a decrease in sexual activity and the enjoyment of sex over the entire HAART period, just as over the speci®c period of experiencing this syndrome. This may indicate that lipodystrophy has a very strong impact on these changes, because these changes are still re¯ected when asked over the entire period of HAART use. On the other hand, a decrease in sexual activity in the period of using HAART was also reported by men who never experienced lipodystrophy, indicating a role of other HAART-related factors, such as the possible sexual dysfunction associated with PI use [8, 9] . Over the period of experiencing lipodystrophy no change was reported in condom use, indicating that a direct impact of lipodystrophy on condom use is not likely. However, men who experienced lipodystrophy did increase their condom use when asked over the entire HAART period (whereas men not reporting lipodystrophy did not). This ®nding probably results from other HAART-related differences between the two groups, although differences in the time since starting HAART or age appeared not to play a role.
In conclusion, a large proportion of HAART recipients experienced lipodystrophy, which probably had a strong impact on the perceived health and con®dence in relationships of these men. An additional decrease in enjoying sex and sexual activity has been noted, although we cannot determine whether this is caused by lipodystrophy, other aspects of HAART, or both. Syphilis and gonorrhoea in Paris: the return We report here on 10 cases of early syphilis in men diagnosed in our sexually transmited diseases (STD) centre in Paris between March and November 2000. We also report a 104% overall increase of bacteriological con®rmed gonococcal infections (BCGI) during the same 9 month study period during 5 years.
It has been reported that an increase in sexual risktaking among San Fransisco gay men has correlated with increasing rates of rectal gonorrhoea in this population [1] . Recently, an increase in the incidence of gonorrhoea in London and in other places in the UK has been reported [2, 3] . In 1999, an epidemiological study in France (the RENAGO study) [4] suggested an increase in the incidence of gonococcal infections between 1997 and 1998. A limited syphilis outbreak has also been reported in the USA [5] , but no information on new cases of early syphilis is available from France.
Between March 2000 and November 2000, one heterosexual man and nine homosexual men consulted at our STD centre for early syphilis. Five patients were HIV positive, three were HIV negative, and the HIV status was unknown in the last two cases because the patients declined a blood test for HIV serology. The mean clinical and biological features of the patients are summarized in Table 1 . Three patients were diagnosed with primary syphilis and seven were diagnosed with secondary syphilis. One HIV-positive patient had previously been hospitalized in 1994 for neurosyphilis, another HIV-positive patient had urethritis 2 weeks before consulting for secondary syphilis, and a third HIV-infected patient had concomitant non-speci®c urethritis. Two HIV-infected patients were undergoing highly active antiretroviral therapy (HAART) combining stavudine, lamivudine and indinavir, with respective CD4 cell counts of 667 and 250/mm 3 , the HIV-RNA plasma viral load was 17 000 copies per ml in one patient and undetectable in the other. The three other HIV-infected patients were not treated with antiviral therapy, their CD4 cell count were 829, 601, and 260/mm 3 , respectively, and their HIV-RNA plasma viral loads were 4490 and 427 copies/ml and not available in the last case. None of the HIV-infected patients had neurosyphilis. Patients were treated with 2.4 3 10 6 units of benzathine penicillin G.
These observations suggest a large increase in high-risk sexual practices among gay men living in Paris, because during the past few years no new cases of early syphilis had been diagnosed at our STD center. This is in accordance with a large increase in gonoccocal infections reported in our center since 1995. In Table 2 , we report the number of BCGI and the total of STD leading to treatment for gonococcal infection, comprising BCGI and urethritis or rectitis suspected of gonococcal origin because of both clinical symptoms and presence of intracellular Gram-negative diplococcus after Gram staining, but which cannot be isolated after culture (total gonococcal infections). As is shown, we observed a 104% overall increase in BCGI, with 23 cases in 1996 and 47 cases in 2000. As is reported, there was also an increase in the proportion of suspected versus BCGI cases since 1997, corresponding with the introduction of HAART for the treatment of HIV-infected patients. It could be that HAART may interact with the culture capacity of Neisseiria gonorrhoeae. This hypothesis needs to be explored further.
The increase in both early syphilis and gonococcal infections contrasts with the decrease in the number of visits to our STD centre, with 6476 consultations for the ®rst 9 months of 1998 falling to 5044 consultations during the same period in 2000 (Table 2 ). We therefore emphasize the need for continued surveillance of these STD in Paris and in other places in France, in order to focus sexual health promotion activities on controling their increasing incidence and preventing the risk of new HIV contaminations.
Partner noti®cation by HIV-1 seropositive pregnant women: association with infant feeding decisions Each year, an estimated 600 000 perinatal HIV-1 infections occur despite the availability of interventions to decrease mother-to-child transmission of HIV-1 [1] . In order to implement perinatal HIV-1 interventions it is necessary to diagnose HIV-1 infection during pregnancy. Even with antenatal HIV-1 counselling and testing, however, pregnant HIV-1 seropositive women in developing countries are often unable to access antiretroviral agents or avoid breastfeeding because of ®nancial constraints and the fear of stigmatization.
Pregnant HIV-1 infected women may choose to notify their spouses/partners of their HIV-1 status in order to gain emotional and ®nancial support. The majority of women, however, do not inform their partners, and encouraging women to notify spouses/partners that they are HIV-1 seropositive remains controversial [2] .
Studies among non-pregnant HIV-1 seropositive women found that less than half of the individuals noti®ed their sexual partners when they learned they were HIV-1 infected [3, 4] . A study among pregnant women found that only 27% chose to notify their spouses/ partners about their positive HIV-1 serostatus [5] . The fear of domestic violence or abandonment is frequently cited as a reason why not all women inform their spouse/partner about their HIV-1 status [6±8].
Voluntary HIV-1 counselling and testing in the antenatal setting provides unique incentives for women to inform spouses/partners about their HIV-1 status and include them in efforts to prevent HIV-1 infection in their unborn child. A better understanding of issues surrounding partner noti®cation in the antenatal setting may lead to the improved uptake of interventions to reduce mother-to-child HIV-1 transmission. 
